High-Impact Vaccine Adjuvant for Influenza and Beyond

Description

This technology is a novel injectable vaccine adjuvant that significantly enhances immune protection, particularly in the context of influenza (flu) vaccination. In preclinical studies using a high-lethality influenza challenge model with commercial flu vaccine, this adjuvant improved survival rates by 60% compared to groups receiving the vaccine alone. In addition to flu, this adjuvant also achieved complete protection against rotavirus (RV) infection in animal models when co-administered with an RV inoculum.

These results highlight its strong potential in improving outcomes during seasonal outbreaks or pandemics. With over 3 million cases of influenza reported annually in the U.S., leading to substantial mortality and morbidity, this technology represents a promising advance in vaccine performance and public health protection.

Benefits

• Boosts Commercial Flu Vaccine Efficacy: In preclinical models using a high-lethality influenza challenge, this adjuvant increased survival rates by 60% compared to vaccine alone.
• Broad-Spectrum Immune Enhancement: Boosts efficacy of both flu and rotavirus vaccines.
• Gut-Friendly: Strengthens vaccine performance without interfering with the body's natural gut bacteria.
• Compatible with Injectable Vaccines: Easily integrated into current immunization platforms.

Applications

• Seasonal and Pandemic Flu Vaccines
• Enhanced Immunization for At-Risk Populations
• Next-Gen Vaccine Development and Reformulation
• Rotavirus Vaccination

Patent Status

•  Patent Pending

Publications

Gut microbiota modulate immune responses to orally and parenterally administered rotavirus in mice | npj Vaccines